Evaluation of Patient-Rated Stiffness Associated With Fibromyalgia: A Post-Hoc Analysis of 4 Pooled, Randomized Clinical Trials of Duloxetine

Clinical Therapeutics

Volumn 34, Issue 4, 2012, Pages 824-837

  Bennett, Robert ^a   Russell, Jon I ^b   Choy, Ernest ^c   Spaeth, Michael ^d   Mease, Philip ^e,f   Kajdasz, Daniel ^g   Walker, Daniel ^h   Wang, Fujun ^h   Chappell, Amy ^i,j  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Arthritis and Osteoporosis Center of South Texas   (United States)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d Rheumatologische Schwerpunktpraxis ^*  (Germany)

^e Seattle Rhumatology Associates   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g Trovis Pharmaceuticals LLC   (United States)

^h Lilly USA   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Correlation; Duloxetine; Fibromyalgia; Pain; Stiffness

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; ARTICLE; BRIEF PAIN INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EUROQOL QUESTIONNAIRE 5; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDIMENSIONAL FATIGUE INVENTORY; MUSCLE STIFFNESS; PAIN ASSESSMENT; POST HOC ANALYSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SHEEHAN DISABILITY SCALE; SHORT FORM 36;

DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; TREATMENT OUTCOME;

EID: 84859600615     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.02.013     Document Type: Article

References (51)

1. Mease P., Arnold L.M., Choy E.H., et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 2009, 36:2318-2329. OMERACT Fibromyalgia Working Group.
2. Mease P.J., Arnold L.M., Crofford L.J., et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum 2008, 59:952-960.
3. Bennett R.M., Jones J., Turk D.C., et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007, 8:27.
4. Hauser W., Zimmer C., Felde E., Kollner V. What are the key symptoms of fibromyalgia?. Results of a survey of the German Fibromyalgia Association. Schmerz 2008, 22:176-183.
5. Pagano T., Matsutani L.A., Ferreira E.A., et al. Assessment of anxiety and quality of life in fibromyalgia patients. Sao Paulo Med J 2004, 122:252-258.
6. Bellamy N., Sothern R.B., Campbell J. Aspects of diurnal rhythmicity in pain, stiffness, and fatigue in patients with fibromyalgia. J Rheumatol 2004, 31:379-389.
7. Wolfe F., Hassett A.L., Katz R.S., et al. Do we need core sets of fibromyalgia domains?. The assessment of fibromyalgia (and other rheumatic disorders) in clinical practice. J Rheumatol 2011, 38:1104-1112.
8. Bennett R.M., Friend R., Jones K.D., et al. The revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 2009, 11:R120.
9. DeLoach L.J., Higgins M.S., Caplan A.B., Stiff J.L. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998, 86:102-106.
10. Bellamy N., Buchanan W.W., Goldsmith C.H., et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1998, 15:1833-1840.
11. Wolfe F. Determinants of WOMAC function, pain and stiffness scores: evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia. Rheumatology (Oxford) 1999, 38:355-361.
12. Ranzolin A., Brenol J.C., Bredemeier M., et al. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 2009, 61:794-800.
13. Lineker S., Badley E., Charles C., et al. Defining morning stiffness in rheumatoid arthritis. J Rheumatol 1999, 26:1052-1057.
14. Clark S., Tindall E., Bennett R.M. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 1985, 12:980-983.
15. Burckhardt C.S., Clark S.R., Bennett R.M. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991, 18:728-733.
16. Bennett R.M., Kamin M., Karim R., Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003, 114:537-545.
17. Arnold L.M., Lu Y., Crofford L.J., et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50:2974-2984.
18. Gendreau R.M., Thorn M.D., Gendreau J.F., et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005, 32:1975-1985.
19. Russell I.J., Perkins A.T., Michalek J.E. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009, 60:299-309. Oxybate SXB-26 Fibromyalgia Syndrome Study Group.
20. Arnold L.M., Russell I.J., Diri E.W., et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008, 9:792-805.
21. Arnold L.M., Gendreau R.M., Palmer R.H., et al. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:2745-2756.
22. Bennett R.M., Clark S.C., Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998, 104:227-231.
23. Arnold L.M., Goldenberg D.L., Stanford S.B., et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007, 56:1336-1344.
24. Arnold L.M., Clauw D.J., Wohlreich M.M., et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials. Prim Care Companion J Clin Psychiatry 2009, 11:237-244.
25. Arnold L.M. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med 2007, 8(Suppl 2):S63-S74.
26. Russell I.J., Mease P.J., Smith T.R., et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008, 136:432-444.
27. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare publication (ADM) 1976, 76-338. National Institute of Mental Health, Bethesda, MD.
28. Arnold L.M., Rosen A., Pritchett Y.L., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005, 119:5-15.
29. Chappell A.S., Bradley L.A., Wiltse C., et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. In J Gen Med 2008, 1:91-102.
30. Arnold L.M., Clauw D., Wang F., et al. Flexible dosed duloxetine in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled trial. J Rheumatol 2010, 37:2578-2586.
31. Wolfe F., Smythe H.A., Yunus M.B., et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
32. Cleeland C.S., Ryan K.M. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994, 23:129-138.
33. Smets E.M., Garssen B., Bonke B., De Haes J.C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995, 39:315-325.
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
35. Sheehan D.V., Harnett-Sheehan K., Raj B.A. The measurement of disability. Int Clin Psychopharmacol 1996, 11(Suppl 3):89-95.
36. Ware J.E., Snow K.K., Kosinski M., Gondeck G. SF-36 Health Survey Manual and Interpretation Guide 1993, The Health Institute, New England Medical Center, Boston, Mass.
37. Kind P. The EuroQoL instrument: an index of health-related quality of life. Quality of Life and Pharmacoeconomics in Clinical Trials 1996, 191-201. Lippincott-Raven Publishers, Philadelphia, Pa. B. Spilker (Ed.).
38. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1977, Lawrence Erlbaum Associates, Inc, Hillsdale, NJ. 2nd ed.
39. Hedges L.V., Olkin I. Examination of a single effect size: parametric and nonparametric methods. Statistical Methods for Meta-Analysis 1985, 75-106. Fl: Academic Press, Inc, Waltham, Mass.
40. Mease P.J., Russell I.J., Arnold L.M., et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008, 35:502-514.
41. Bennett R.M., Bushmakin A.G., Cappelleri J.C., et al. Minimal clinically important difference in the Fibromyalgia Impact Questionnaire. J Rheumatol 2009, 36:1304-1311.
42. Assumpção A., Cavalcante A.B., Capela C.E., et al. Prevalence of fibromyalgia in a low socioeconomic status population. BMC Musculoskelet Disord 2009, 10:64.
43. Wolfarth S., Lorenc-Koci E., Schulze G., et al. Age-related muscle stiffness: predominance of non-reflex factors. Neuroscience 1997, 79:617-628.
44. Dierick F., Detrembleur C., Trintignac G., Masquelier E. Nature of passive musculoarticular stiffness increase of ankle in female subjects with fibromyalgia syndrome. Eur J Appl Physiol 2011, 111:2163-2171.
45. Yunus M.B., Arslan S., Aldag J.C. Relationship between body mass index and fibromyalgia features. Scand J Rheumatol 2002, 31:27-31.
46. Bennett R.M., Schein J., Kosinski M.R., et al. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 2005, 53:519-527.
47. McNair P.J., Stanley S.N. Effect of passive stretching and jogging on the series elastic muscle stiffness and range of motion of the ankle joint. Br J Sports Med 1996, 30:313-317.
48. Khan N.A., Yazici Y., Calvo-Alen J., et al. Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. J Rheumatol 2009, 36:2435-2442. QUEST-RA Group.
49. Seldenrijk A., van Hout H.P., van Marwijk H.W., et al. Depression, anxiety, and arterial stiffness. Biol Psychiatry 2011, 69:795-803.
50. Brunton S., Wang F., Edwards S.B., et al. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf 2010, 33:393-407.
51. Choy E.H.S., Mease P.J., Kajdasz D.K., et al. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Clin Rheumatol 2009, 28:1035-1044.